Olema Pharmaceuticals (OLMA) Projected to Post Quarterly Earnings on Tuesday

by · The Cerbat Gem

Olema Pharmaceuticals (NASDAQ:OLMA – Get Free Report) will likely be announcing its Q3 2025 results before the market opens on Tuesday, November 11th. Analysts expect the company to announce earnings of ($0.44) per share for the quarter. Investors may visit the the company’s upcoming Q3 2025 earningresults page for the latest details on the call scheduled for Tuesday, November 18, 2025 at 7:00 AM ET.

Olema Pharmaceuticals (NASDAQ:OLMA – Get Free Report) last issued its earnings results on Monday, August 11th. The company reported ($0.51) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.43) by ($0.08). On average, analysts expect Olema Pharmaceuticals to post $-2 EPS for the current fiscal year and $-3 EPS for the next fiscal year.

Olema Pharmaceuticals Stock Performance

OLMA stock traded up $0.02 during midday trading on Tuesday, reaching $8.44. 137,333 shares of the company’s stock traded hands, compared to its average volume of 970,730. The company has a 50-day moving average price of $8.54 and a two-hundred day moving average price of $6.11. The company has a debt-to-equity ratio of 0.01, a quick ratio of 11.09 and a current ratio of 11.09. Olema Pharmaceuticals has a 52 week low of $2.86 and a 52 week high of $13.51. The firm has a market capitalization of $579.00 million, a PE ratio of -4.26 and a beta of 2.08.

Analyst Upgrades and Downgrades

A number of research analysts recently commented on OLMA shares. Zacks Research raised Olema Pharmaceuticals from a “strong sell” rating to a “hold” rating in a research note on Tuesday, September 9th. Weiss Ratings reissued a “sell (d-)” rating on shares of Olema Pharmaceuticals in a research note on Wednesday, October 8th. HC Wainwright reiterated a “buy” rating and set a $28.00 target price on shares of Olema Pharmaceuticals in a report on Monday, October 20th. UBS Group reiterated a “buy” rating on shares of Olema Pharmaceuticals in a report on Monday, October 20th. Finally, JPMorgan Chase & Co. increased their target price on shares of Olema Pharmaceuticals from $28.00 to $29.00 and gave the stock an “overweight” rating in a report on Thursday, August 14th. Seven research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $23.00.

Read Our Latest Analysis on Olema Pharmaceuticals

Insiders Place Their Bets

In other Olema Pharmaceuticals news, Director Cyrus Harmon sold 3,086 shares of the firm’s stock in a transaction that occurred on Thursday, September 18th. The shares were sold at an average price of $8.32, for a total transaction of $25,675.52. Following the completion of the transaction, the director owned 117,028 shares of the company’s stock, valued at approximately $973,672.96. This trade represents a 2.57% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Over the last quarter, insiders sold 25,000 shares of company stock worth $204,841. Insiders own 16.36% of the company’s stock.

Hedge Funds Weigh In On Olema Pharmaceuticals

A number of institutional investors and hedge funds have recently made changes to their positions in the business. Thrivent Financial for Lutherans bought a new position in shares of Olema Pharmaceuticals during the second quarter valued at approximately $308,000. Bridgeway Capital Management LLC bought a new stake in shares of Olema Pharmaceuticals during the second quarter valued at approximately $213,000. Ameriprise Financial Inc. increased its position in shares of Olema Pharmaceuticals by 193.4% during the second quarter. Ameriprise Financial Inc. now owns 1,172,863 shares of the company’s stock valued at $4,996,000 after acquiring an additional 773,064 shares in the last quarter. The Manufacturers Life Insurance Company increased its position in shares of Olema Pharmaceuticals by 46.7% during the second quarter. The Manufacturers Life Insurance Company now owns 22,442 shares of the company’s stock valued at $96,000 after acquiring an additional 7,146 shares in the last quarter. Finally, Invesco Ltd. increased its position in shares of Olema Pharmaceuticals by 57.3% during the second quarter. Invesco Ltd. now owns 79,929 shares of the company’s stock valued at $340,000 after acquiring an additional 29,119 shares in the last quarter. Institutional investors own 91.78% of the company’s stock.

Olema Pharmaceuticals Company Profile

(Get Free Report)

Olema Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women’s cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 3 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer; and OP-1250 combine with CDK4/6 inhibitors palbociclib, ribociclib, and alpelisib in Phase 1/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive human epidermal growth factor receptor 2-negative breast cancer, as well as develops OPERA-01 for the of ER+/HER2- advanced or metastatic breast cancer.

See Also